Daniel Dubin - Dec 23, 2021 Form 4/A - Amendment Insider Report for PARDES BIOSCIENCES, INC. (PRDS)

Role
Director
Signature
/s/ Dennis Ryan, as Attorney-in-Fact
Stock symbol
PRDS
Transactions as of
Dec 23, 2021
Transactions value $
$0
Form type
4/A - Amendment
Date filed
12/30/2021, 03:00 PM
Date Of Original Report
Dec 28, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRDS Class A Common Stock Conversion of derivative security $0 +30K $0.00 30K Dec 23, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRDS Class B Common Stock Conversion of derivative security $0 -30K -100% $0.00* 0 Dec 23, 2021 Class A Common Stock 30K $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Daniel Dubin is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into shares of Class A Common Stock of the Issuer.

Remarks:

On December 28, 2021, the reporting person filed a Form 4 which contained a clerical error reporting that the reporting person beneficially owned 52,500 shares of Class B Common Stock of FS Development Corp. II prior to its business combination. In fact, as reported in this Form 4, the reporting person beneficially owned 30,000 shares of Class B Common Stock.